Loading...

Alliance Pharma

DB:DVL
Snowflake Description

Established dividend payer with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DVL
DB
£404M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Alliance Pharma has significant price volatility in the past 3 months.
DVL Share Price and Events
7 Day Returns
0.8%
DB:DVL
-0.6%
DE Pharmaceuticals
1.8%
DE Market
1 Year Returns
-
DB:DVL
-21.5%
DE Pharmaceuticals
-6%
DE Market
DVL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alliance Pharma (DVL) 0.8% 23.5% 27.4% - - -
DE Pharmaceuticals -0.6% -1.6% -2.3% -21.5% -26.2% 8.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on DVL.
  • No trading data on DVL.
Price Volatility
DVL
Industry
5yr Volatility vs Market

Value

 Is Alliance Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Alliance Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Alliance Pharma.

DB:DVL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DVL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 19%) (24.55%))
0.915
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.915 * 6.65%)
6.31%

Discounted Cash Flow Calculation for DB:DVL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Alliance Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DVL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 6.31%)
2019 27.30 Analyst x1 25.68
2020 28.30 Analyst x2 25.04
2021 31.90 Analyst x1 26.55
2022 34.59 Est @ 8.45% 27.08
2023 36.66 Est @ 5.98% 26.99
2024 38.22 Est @ 4.25% 26.47
2025 39.39 Est @ 3.05% 25.66
2026 40.25 Est @ 2.2% 24.66
2027 40.90 Est @ 1.61% 23.57
2028 41.39 Est @ 1.19% 22.44
Present value of next 10 years cash flows £254.14
DB:DVL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £41.39 × (1 + 0.23%) ÷ (6.31% – 0.23%)
£681.59
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £681.59 ÷ (1 + 6.31%)10
£369.48
DB:DVL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £254.14 + £369.48
£623.62
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £623.62 / 518.23
£1.2
DB:DVL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DVL represents 1.1412x of AIM:APH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.1412x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 1.20 x 1.1412
€1.37
Value per share (EUR) From above. €1.37
Current discount Discount to share price of €0.89
= -1 x (€0.89 - €1.37) / €1.37
35.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Alliance Pharma is available for.
Intrinsic value
35%
Share price is €0.89 vs Future cash flow value of €1.37
Current Discount Checks
For Alliance Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Alliance Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Alliance Pharma's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alliance Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alliance Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DVL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £0.04
AIM:APH Share Price ** AIM (2019-04-18) in GBP £0.78
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 26.82x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alliance Pharma.

DB:DVL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:APH Share Price ÷ EPS (both in GBP)

= 0.78 ÷ 0.04

21.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alliance Pharma is good value based on earnings compared to the DE Pharmaceuticals industry average.
  • Alliance Pharma is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Alliance Pharma's expected growth come at a high price?
Raw Data
DB:DVL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 21.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
17.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.76x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:DVL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 21.1x ÷ 17.3%

1.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alliance Pharma is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Alliance Pharma's assets?
Raw Data
DB:DVL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £0.49
AIM:APH Share Price * AIM (2019-04-18) in GBP £0.78
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.39x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:DVL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:APH Share Price ÷ Book Value per Share (both in GBP)

= 0.78 ÷ 0.49

1.6x

* Primary Listing of Alliance Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alliance Pharma is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Alliance Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Alliance Pharma has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Alliance Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alliance Pharma expected to grow at an attractive rate?
  • Alliance Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Alliance Pharma's earnings growth is expected to exceed the Germany market average.
  • Alliance Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DVL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DVL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 17.3%
DB:DVL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 10%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.7%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DVL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DVL Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 164 39 32 2
2020-12-31 155 36 28 3
2019-12-31 145 33 26 3
DB:DVL Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 118 22 18
2018-09-30 112 24 21
2018-06-30 108 25 24
2018-03-31 106 26 27
2017-12-31 102 27 29
2017-09-30 101 27 25
2017-06-30 100 26 22
2017-03-31 99 22 20
2016-12-31 97 17 18
2016-09-30 85 13 18
2016-06-30 72 9 18
2016-03-31 60 9 15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alliance Pharma's earnings are expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).
  • Alliance Pharma's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DVL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Alliance Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DVL Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.06 0.06 0.06 1.00
2020-12-31 0.05 0.05 0.05 2.00
2019-12-31 0.05 0.05 0.05 1.00
DB:DVL Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 0.04
2018-09-30 0.04
2018-06-30 0.05
2018-03-31 0.06
2017-12-31 0.06
2017-09-30 0.05
2017-06-30 0.05
2017-03-31 0.04
2016-12-31 0.04
2016-09-30 0.04
2016-06-30 0.05
2016-03-31 0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Alliance Pharma is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Alliance Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alliance Pharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Alliance Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alliance Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alliance Pharma has delivered over 20% year on year earnings growth in the past 5 years.
  • Alliance Pharma's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Alliance Pharma's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.
Earnings and Revenue History
Alliance Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alliance Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DVL Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 118.21 18.36 43.72
2018-09-30 112.47 21.28 40.21
2018-06-30 108.40 24.29 36.51
2018-03-31 105.86 26.60 34.83
2017-12-31 101.64 28.83 33.35
2017-09-30 101.07 25.40 32.70
2017-06-30 100.49 21.97 32.05
2017-03-31 98.99 20.03 30.79
2016-12-31 97.49 18.09 29.54
2016-09-30 84.71 17.99 25.86
2016-06-30 71.92 17.89 22.18
2016-03-31 60.13 15.29 19.31
2015-12-31 48.34 12.69 16.45
2015-09-30 46.63 10.50 15.52
2015-06-30 44.91 8.31 14.59
2015-03-31 44.22 8.35 13.84
2014-12-31 43.54 8.39 13.08
2014-09-30 43.73 8.46 13.22
2014-06-30 43.92 8.54 13.37
2014-03-31 44.60 9.06 13.46
2013-12-31 45.28 9.58 13.55
2013-09-30 45.59 9.72 13.24
2013-06-30 45.67 9.85 12.87
2013-03-31 45.29 9.27 12.55
2012-12-31 44.90 8.69 12.23
2012-09-30 44.23 8.00 11.86
2012-06-30 43.57 7.32 11.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Alliance Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Alliance Pharma used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Alliance Pharma has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Alliance Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alliance Pharma has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Alliance Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alliance Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alliance Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Alliance Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Alliance Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alliance Pharma Company Filings, last reported 3 months ago.

DB:DVL Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 252.20 99.13 10.89
2018-09-30 252.20 99.13 10.89
2018-06-30 241.42 100.80 14.48
2018-03-31 241.42 100.80 14.48
2017-12-31 203.11 86.22 11.18
2017-09-30 203.11 86.22 11.18
2017-06-30 187.39 72.68 9.01
2017-03-31 187.39 72.68 9.01
2016-12-31 179.26 83.72 7.22
2016-09-30 179.26 83.72 7.22
2016-06-30 168.02 83.58 3.94
2016-03-31 168.02 83.58 3.94
2015-12-31 162.44 74.90 3.23
2015-09-30 162.44 74.90 3.23
2015-06-30 73.05 27.04 0.50
2015-03-31 73.05 27.04 0.50
2014-12-31 70.78 22.67 1.43
2014-09-30 70.78 22.67 1.43
2014-06-30 67.04 25.93 0.43
2014-03-31 67.04 25.93 0.43
2013-12-31 64.67 25.90 0.69
2013-09-30 64.67 25.90 0.89
2013-06-30 57.22 30.77 1.48
2013-03-31 57.22 30.77 1.48
2012-12-31 51.85 30.67 4.63
2012-09-30 51.85 30.67 4.63
2012-06-30 46.98 21.83 3.16
  • Alliance Pharma's level of debt (39.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (40% vs 39.3% today).
  • Debt is well covered by operating cash flow (22.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 8.6x coverage).
X
Financial health checks
We assess Alliance Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alliance Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Alliance Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.88%
Current annual income from Alliance Pharma dividends. Estimated to be 2.25% next year.
If you bought €2,000 of Alliance Pharma shares you are expected to receive €38 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Alliance Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • Alliance Pharma's dividend is below the markets top 25% of dividend payers in Germany (3.71%).
Upcoming dividend payment

Purchase Alliance Pharma before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DVL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DVL Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.02 2.00
2020-12-31 0.02 3.00
2019-12-31 0.02 3.00
DB:DVL Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2019-04-16 0.015 1.863
2018-04-19 0.013 1.762
2018-03-27 0.013 1.812
2017-03-29 0.012 2.138
2016-04-28 0.011 2.359
2016-04-07 0.011 2.360
2015-04-10 0.010 2.070
2015-03-25 0.010 2.682
2014-03-26 0.009 2.688
2013-03-21 0.008 2.344
2012-03-27 0.008 2.569
2012-03-22 0.008 2.620
2011-03-23 0.006 1.880
2011-03-22 0.006 1.775
2010-09-08 0.003 1.007
2010-07-15 0.003 0.970
2010-03-24 0.003 0.909
2009-09-09 0.001 0.605

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Alliance Pharma's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).
X
Income/ dividend checks
We assess Alliance Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alliance Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alliance Pharma has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Alliance Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Butterfield
COMPENSATION £306,710
AGE 42
TENURE AS CEO 0.9 years
CEO Bio

Mr. Peter Jonathan Butterfield has been Chief Executive Officer of Alliance Pharma plc since May 01, 2018. Mr. Butterfield served as Deputy Chief Executive Officer and Chief Operating Officer of Alliance Pharma plc from June 2017 to May 1, 2018 and served as its Chief Commercial Officer November 23, 2015. He served as Director of UK at Alliance Pharma plc until November 23, 2015 and also served as its Portfolio Director of Oncology & Dermatology. Mr. Butterfield served as UK Commercial Manager at Cambridge Laboratories. Prior to joining Cambridge Laboratories, Mr. Butterfield spent six years at SmithKline Beecham (now GlaxoSmithKline), where he acquired extensive sales and marketing knowledge. Mr. Butterfield serves as Executive Director at Cambridge Laboratories Limited. He has been an Executive Director of Alliance Pharma plc since February 2010 and served as Director of Cambridge Laboratories. He serves as a Board Member of the Association of the British Pharmaceutical Industry (ABPI) and serves as chairman of the ABPI Small Companies Forum. Mr. Butterfield holds an honours degree in Pharmacology from the University of Edinburgh.

CEO Compensation
  • Peter's compensation has been consistent with company performance over the past year.
  • Peter's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alliance Pharma management team in years:

4.3
Average Tenure
52
Average Age
  • The tenure for the Alliance Pharma management team is about average.
Management Team

Peter Butterfield

TITLE
CEO & Executive Director
COMPENSATION
£307K
AGE
42
TENURE
0.9 yrs

John Dawson

TITLE
Founder & Non-Executive Director
COMPENSATION
£434K
AGE
69
TENURE
23.3 yrs

Andrew Franklin

TITLE
CFO & Executive Director
COMPENSATION
£227K
AGE
52
TENURE
3.6 yrs

Stephen Kidner

TITLE
Chief Scientific & Operations Officer

Dan Thomas

TITLE
Chief Corporate Development Officer

Janice Timberlake

TITLE
Chief Human Resources Officer

Steve Lobb

TITLE
Head of Hydromol

David Hope

TITLE
Head of Secondary Care

Alex Duggan

TITLE
Chief Commercial Officer
TENURE
4.9 yrs

Rajiv Ghidiyal

TITLE
Head of APAC
Board of Directors Tenure

Average tenure and age of the Alliance Pharma board of directors in years:

2.3
Average Tenure
52
Average Age
  • The average tenure for the Alliance Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Cook

TITLE
Independent Non-Executive Chairman
COMPENSATION
£38K
AGE
51
TENURE
1.1 yrs

Peter Butterfield

TITLE
CEO & Executive Director
COMPENSATION
£307K
AGE
42
TENURE
9.2 yrs

John Dawson

TITLE
Founder & Non-Executive Director
COMPENSATION
£434K
AGE
69

Andrew Franklin

TITLE
CFO & Executive Director
COMPENSATION
£227K
AGE
52
TENURE
3.6 yrs

Nigel Clifford

TITLE
Independent Non-Executive Director
COMPENSATION
£36K
AGE
59
TENURE
4.3 yrs

Richard Crispin Jones

TITLE
Independent Non-Executive Director
AGE
52
TENURE
0.3 yrs

Jo LeCouilliard

TITLE
Independent Non-Executive Director
AGE
55
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alliance Pharma insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Jan 19 Buy Richard Crispin Jones Individual 22. Jan 19 22. Jan 19 15,000 €0.74 €11,167
12. Nov 18 Sell John Dawson Individual 09. Nov 18 09. Nov 18 -1,100,000 €0.80 €-883,633
X
Management checks
We assess Alliance Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alliance Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The company acquires, markets, and sells pharmaceutical products. It acquires the rights of established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. In addition, it offers products in various therapeutic areas, including acquired healthcare, cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology, travel health, urology, vitamins and minerals, and others. Further, the company provides the Kelo-Cote, a formula silicone treatment used for prevention and forming of scars; MacuShield, an eye care supplement; and Vamousse, a pesticide free consumer healthcare product for prevention and treatment of human heal lice. The company distributes its products through wholesalers, retail pharmacies, hospitals, and network of distributors. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Details
Name: Alliance Pharma plc
DVL
Exchange: DB
Founded: 1996
£466,650,967
518,230,255
Website: http://www.alliancepharmaceuticals.com
Address: Alliance Pharma plc
Avonbridge House,
Bath Road,
Chippenham,
Wiltshire, SN15 2BB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM APH Ordinary Shares London Stock Exchange AIM Market GB GBP 23. Dec 2003
DB DVL Ordinary Shares Deutsche Boerse AG DE EUR 23. Dec 2003
Number of employees
Current staff
Staff numbers
200
Alliance Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:12
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.